Replies to post #192272 on Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

I assume a K partnership is definitely being planned. That is the purpose of doing their small K-OC trial to obtain tumor samples to prove the mechanism of P53. Concurrently, they are working on an oral formulation. Together, an oral formulation that targets P53 with minimal side effects and toxicity will be a major breakthrough in the oncology field that has not been achieved in 20+ years. An initial partnership on Kevetrin alone will likely translate to 10x returns on current investment.